In rodents, Amphista linked its BRD9 degrader AMX-883 to a significant improvement in survival and reduction in disease burden compared to Venclexta. Combining AMX-883 with Venclexta and azacitidine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback